Adaptive ultra-hypofractionated whole-pelvic radiotherapy in high-risk and very high-risk prostate cancer on 1.5-Tesla MR-Linac: Estimated delivered dose and early toxicity results.
Lin-Rui GaoRan WeiShirui QinYuan TianWenlong XiaYongwen SongShulian WangHui FangYu TangHao JingYueping LiuYuan TangShunan QiBo ChenYexiong LiNianzeng XingNingning LuPublished in: Chronic diseases and translational medicine (2024)
Chinese Clinical Trial Registry ChiCTR2000033382.
Keyphrases
- prostate cancer
- clinical trial
- radiation therapy
- magnetic resonance
- radical prostatectomy
- early stage
- locally advanced
- rectal cancer
- oxidative stress
- high resolution
- radiation induced
- phase ii
- study protocol
- open label
- double blind
- magnetic resonance imaging
- randomized controlled trial
- squamous cell carcinoma
- computed tomography